Start here if you're new
what it is
Ascent makes industrial chemicals and metal tubing products used in oil, water, construction, and manufacturing.
how it gets paid
FY2025 net sales were ~$74.9M on a continuing / specialty-chemicals comparable basis—down ~7.3% from ~$80.8M in FY2024 (not the old multi-segment ~$178M consolidated headline from before tubular divestitures).
why growth slowed
Revenue fell 7.3% last year to $74.9M. Gross margin expanded to 23.0% for the year and 29.7% in Q3 — the strongest reading in years, suggesting the turnaround may be real.
what just happened
FY2025 ended with ~$57.6M cash, no borrowings on the revolver, and a net loss of ~$5.6M (~$(0.58) diluted EPS)—better than FY2024, still not “profitable.”
At a glance
B balance sheet — gets the job done, barely
5/100 earnings predictability — expect surprises
n/a trailing p/e — negative earnings
still GAAP-negative FY2025 — return metrics are noisy until earnings turn
-$0.58 fy2025 eps
xvary composite: 51/100 — below average
What they do
Ascent makes industrial chemicals and metal tubing products used in oil, water, construction, and manufacturing.
The moat here is not brand magic. It is balance-sheet survival: post-divestiture cash in the ~$50–60M range with no revolver borrowings (per earnings materials), while non-current lease obligations—not a classic bond stack—still matter for fixed commitments.
How they make money
~$74.9M
FY2025 net sales (specialty chemicals comparable) · down ~7.3% vs. ~$80.8M FY2024 comparable
total revenue
~$74.9M
7.3%
FY2025 / Q4’25: company materials (e.g. FY2025 earnings PR, Mar 2026). Q3’25 detail: Business Wire Nov 4, 2025.
The products that matter
manufactures specialty chemicals
Industrial Chemicals
FY2025 ~$74.9M sales · 23.0% gross margin
Pure-play specialty chemicals after tubular divestitures: FY2025 ~$74.9M net sales, 23.0% gross margin, still GAAP loss (~$(0.58) diluted EPS). The case is whether margin structure converts to durable operating income.
remaining business
Key numbers
23.0%
FY2025 gross margin
Up from 13.2% in FY2024 (comparable basis)—the cleanest year-over-year proof the chemicals model is repricing gross profit.
n/a
trailing p/e
Trailing P/E → not applicable because earnings are negative. You cannot calculate a meaningful P/E ratio on a loss-making company.
~$19M
non-current leases
Sep 30, 2025 balance sheet: no revolver borrowings; large non-current lines are mostly operating/finance lease obligations (~$19M non-current lease liabilities in the Q3’25 tables)—not a big term-loan tower.
~$58M
cash (Sep 30, ’25)
FY2025 PR cites ~$57.6M cash at year-end—order of magnitude matches post-divestiture liquidity; check each filing for exact date.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 40 / 100
- revolver / term debt no revolver draw (per Q3’25 PR); ~$19M non-current lease liabilities
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ACNT right now.
source: institutional data · return history unavailable
What just happened
FY2025 filed
FY2025 net sales ~$74.9M (−7.3% vs. ~$80.8M FY2024 comparable); gross margin 23.0%; diluted EPS ~$(0.58). Q4’25 sales ~$18.8M.
Q3’25 was the margin “show” quarter (29.7% gross margin on $19.7M sales). Q4’25 had lower quarterly gross margin—use FY2025 for the thesis. Net loss ~$5.6M FY2025; cash ~$57.6M at year-end with no revolver debt per FY2025 materials.
~$74.9M
FY2025 sales
~$(0.58)
FY diluted EPS
23.0%
FY gross margin
the number that mattered
Whether 23% gross margin survives mixed quarterly demand—and converts to operating income—now that tubular divestitures are behind you.
source: FY2025 summary (Mar 2026 earnings materials); Q3’25: Business Wire Nov 4, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is management missing its promised double-digit 2026 revenue growth.
med
missed 2026 growth target
management has framed 2026 around double-digit revenue growth from new commercial programs. after a ~7.3% revenue decline, that target now carries most of the reset story.
if growth does not show up, you are left with a loss-making chemicals stub where the bull case is margin + balance sheet, not reported net income.
med
margin repair fades
gross margin improved to 23.0% from 13.2% in 2024. that is the strongest operating evidence the turnaround is working.
if margin slips back while revenue stays weak, the earnings recovery disappears fast because there is no second segment to absorb the miss.
med
single-segment concentration
after selling the pipe business, you no longer have diversification. this is one chemicals segment, one commercial pipeline, and one set of end markets.
that concentration exposes essentially all $74.9M of revenue to the same execution story.
the combined risk picture is simple: a one-segment company with $74.9M of revenue and a FY loss (EPS ~-$0.58) is being valued at ~$121M because investors expect better numbers next. those better numbers need to arrive soon.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Q1 2026 earnings report
estimated for may 12, 2026. this is the first real check on whether double-digit growth is becoming visible or staying in management commentary.
margin
gross margin holding near 23%
23.0% is the best number on the page. if you see that slip while revenue stays soft, the reset story gets a lot less interesting.
commercial
new program wins turning into sales
watch for concrete updates on customer programs and revenue timing. for ACNT, pipeline language needs to become reported revenue.
capital
buyback execution, not just authorization
the board authorized a 2M share repurchase program through 2027. authorization is cheap. actual repurchases tell you how management wants to use that $57.6M cash pile.
Analyst rankings
earnings predictability
5 / 100
that score means earnings have been hard to model. in human-speak, you should expect volatility rather than smooth quarterly progress.
source: institutional data
Institutional activity
institutional ownership data for ACNT is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$16
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive